In the end, whether they be via reimbursement/rebate or direct sales, sales are sales and so far nothing from regions that they have been able to sell in such as Europe and parts of South America which should be a concern to any investor in this company. Maybe the Endo product will be the one that breaks for this company.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)